Novartis | NOVN - PE Price to Earnings


Novartis reported 22.41 in PE Price to Earnings for its fiscal quarter ending in June of 2026.





Pe Change Date
AbbVie 23.96 0.93 Jun/2026
Alcon AG 42.44 6.03 Jun/2026
Almirall 79.43 0.3 Dec/2025
Amgen 18.07 1.77 Jun/2026
AstraZeneca 25.34 4.25 Jun/2026
Bayer 4.14 0.74 Jun/2026
Biogen 23.23 9.53 Jun/2026
Bristol-Myers Squibb 16.14 7.06 Jun/2026
Eli Lilly 32.9 7.37 Jun/2026
Fresenius 11.44 4.91 Jun/2026
Fresenius Medical Care 12.13 5.49 Jun/2026
Genmab 16.04 1.05 Jun/2026
Gilead Sciences 13.51 4.2 Jun/2026
GlaxoSmithKline 10.63 4.24 Jun/2026
GRIFOLS 14.71 3.73 Jun/2026
Hikma Pharmaceutical 10.43 3.72 Dec/2025
J&J 29.43 4.9 Jun/2026
Lakefront Biotherapeutics 2.68 0.14 Jun/2026
Lonza 34.34 2.58 Dec/2025
Merck 17.21 4.47 Jun/2026
Merck 32.26 15.74 Jun/2026
Novartis 22.41 2.24 Jun/2026
Novartis 21.36 3.57 Mar/2026
Novo Nordisk 10.17 2.61 Jun/2026
Orion 17.23 1.3 Jun/2026
Pfizer 11.48 2.16 Jun/2026
Philips 23.76 9.44 Jun/2026
Recordati 22.75 5.09 Jun/2026
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Roche Holding 16.48 0.39 Jun/2026
Sanofi 18.96 7.12 Jun/2026
UCB 29.7 5.52 Dec/2025